|
AGBL5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.5613961192953E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.31130004024749E-10 |
| Normal-vs-Stage2 |
2.538300E-02 |
| Normal-vs-Stage3 |
2.06559991333677E-10 |
| Normal-vs-Stage4 |
1.6581000017446E-08 |
| Stage1-vs-Stage2 |
1.743880E-02 |
| Stage1-vs-Stage3 |
4.839600E-01 |
| Stage1-vs-Stage4 |
5.387600E-01 |
| Stage2-vs-Stage3 |
8.260500E-03 |
| Stage2-vs-Stage4 |
1.073820E-02 |
| Stage3-vs-Stage4 |
9.331800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.20468129600249E-12 |
| Normal-vs-AfricanAmerican |
1.439890E-02 |
| Normal-vs-Asian |
9.09119999947805E-07 |
| Caucasian-vs-AfricanAmerican |
4.958100E-02 |
| Caucasian-vs-Asian |
8.396400E-01 |
| AfricanAmerican-vs-Asian |
1.245030E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.59009999944892E-07 |
| Normal-vs-Female |
6.63500365760683E-11 |
| Male-vs-Female |
5.694600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.74319489135655E-11 |
| Normal-vs-Age(41-60Yrs) |
9.40020283834997E-11 |
| Normal-vs-Age(61-80Yrs) |
1.601790E-04 |
| Normal-vs-Age(81-100Yrs) |
1.902000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.227000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.795800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.480000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.329600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.265400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.187600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.853550E-02 |
| Classical-VS-Follicular |
9.956500E-03 |
| Classical-VS-Other |
3.669800E-01 |
| Classical-VS-Normal |
7.02193858614919E-12 |
| Tall-VS-Follicular |
1.972300E-04 |
| Tall-VS-Other |
9.259200E-01 |
| Tall-VS-Normal |
1.89970039699006E-10 |
| Follicular-VS-Other |
1.477210E-01 |
| Follicular-VS-Normal |
2.441200E-03 |
| Other-VS-Normal |
1.098130E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.49730000024107E-07 |
| Normal-vs-N1 |
7.84894371719247E-12 |
| N0-vs-N1 |
9.591900E-04 |
|
|
